Promising HIV Treatment Insights from Inflammatory Bowel Disease Research

Overview of Inflammatory Bowel Disease

Recent research has revealed encouraging possibilities for HIV treatment, indicating that medications used for inflammatory bowel disease (IBD) may play a role in combating HIV. IBD encompasses a set of chronic disorders characterized by persistent inflammation in the digestive tract. This condition arises primarily from an immune system malfunction that fails to eliminate inflammation triggered by environmental factors. Unlike healthy individuals, IBD patients experience long-lasting inflammatory responses due to this ongoing inflammation.

T Cells and IBD Treatment Strategies

A key approach to managing IBD has involved targeting a specific type of immune cell known as T cells, which express the a4ß7 protein. This protein is crucial for the mobilization of immune cells to various regions within the gastrointestinal tract.

HIV’s Preference for Gut Infections

Intriguingly, the gut also serves as a favored location for HIV infections. Even after the initial infection is cleared, gut cells can harbor a latent reservoir of HIV-infected T cells, hindering complete eradication of the virus. Consequently, a primary objective for researchers in the field of HIV treatment is to develop methods that reduce HIV infection in the gut.

Study Findings from Icahn School of Medicine

A study spearheaded by researchers at the Icahn School of Medicine in New York found that vedolizumab, a drug typically prescribed for IBD, could effectively eliminate clusters of HIV-infected immune cells in the digestive tract. The findings, published in Science Translational Medicine, involved administering vedolizumab to six patients suffering from both HIV and inflammatory bowel diseases. The researchers conducted colonoscopies and collected immune aggregates before and after treatment.

Impact on Inflammatory Bowel Disease and Immune Cells

Remarkably, the study demonstrated that vedolizumab not only alleviated symptoms of inflammatory bowel disease but also significantly decreased the presence of immune cell clusters in the ileum, the final section of the small intestine. Within these immune cell aggregates, the drug specifically activated T cells expressing the a4ß7 protein, which are known to serve as a major reservoir for latent HIV. Additionally, the treatment reduced B cell subsets within these immune patches.

Safety and Future Research Directions

Another encouraging aspect of the study was the drug’s favorable tolerance among patients, with no major side effects reported. However, the authors noted that the absence of FDA approval for using vedolizumab in HIV patients limited the study’s size and scope. Despite this, the findings suggest that exploring drugs aimed at immune receptors could be a valuable avenue for treating various human diseases.

Authorship and Reference

Written by Vinayak Khattar, Ph.D., M.B.A.
Reference: Uzzan, M., Tokuyama, M., Rosenstein, A. K., Tomescu, C., SahBandar, I. N., Ko, H. M., … Mehandru, S. (2018). Anti-alpha4beta7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1-infected individuals. Sci Transl Med, 10(461). doi:10.1126/scitranslmed.aau4711